AbbVie logo

Latest headlines

AbbVie News

The latest AbbVie (ABBV) news, aggregated as it breaks. News moves sentiment and sentiment moves price, so read these ABBV headlines next to the live AbbVie Fear and Greed Index.

Latest AbbVie Headlines60

AbbVie Inc. $ABBV Position Increased by Allspring Global Investments Holdings LLC

defenseworld.net · Jul 18, 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

prnewswire.com · Jul 17, 2026

Will AbbVie's Neuroscience Franchise Deliver Another Strong Quarter?

zacks.com · Jul 16, 2026

Should You Buy, Sell or Hold ABBV Stock After Its 9% YTD Rise?

zacks.com · Jul 15, 2026

AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It

zacks.com · Jul 15, 2026

AbbVie vs Baxter: One Golden Cross Is Real, One Is a Trap

247wallst.com · Jul 15, 2026

Is AbbVie (ABBV) a Buy as Wall Street Analysts Look Optimistic?

zacks.com · Jul 14, 2026

Which High-Yield ETF Is a Better Buy in 2026: Vanguard VYM vs iShares HDV?

fool.com · Jul 14, 2026

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

prnewswire.com · Jul 14, 2026

Donald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibb

fool.com · Jul 14, 2026

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

etftrends.com · Jul 13, 2026

3 Dividend Stocks Built for Long-Term Buy-and-Hold Investors

fool.com · Jul 13, 2026

AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty

fool.com · Jul 11, 2026

AbbVie Inc (ABBV) Stock Down 0.7% but Still Overvalued -- GF Score: 76/100

gurufocus.com · Jul 10, 2026

Johnson & Johnson vs AbbVie: Two Paths to Pharma Dominance, One Winner

247wallst.com · Jul 10, 2026

AbbVie (ABBV) Stock Drops Despite Market Gains: Important Facts to Note

zacks.com · Jul 9, 2026

WST Completes SmartDose Sale to AbbVie to Focus on Core Growth

zacks.com · Jul 9, 2026

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

fool.com · Jul 9, 2026

EU Approves Expanded Use of ABBV's Tepkinly in Follicular Lymphoma

zacks.com · Jul 7, 2026

Buy these quality, low-stress stocks for the summer, says Jefferies

cnbc.com · Jul 7, 2026

3 High-Yield Dividend Stocks to Buy and Hold Forever (Hint: AbbVie Makes the List)

fool.com · Jul 7, 2026

3 Dividend Aristocrats to Buy in July

247wallst.com · Jul 7, 2026

The Dividend ETF Quietly Outperforming the S&P 500

fool.com · Jul 7, 2026

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

prnewswire.com · Jul 6, 2026

Will Immunology Franchise Aid AbbVie's Upcoming Q2 Results?

zacks.com · Jul 6, 2026

Social Security Pays $2,081 a Month. Here’s How Much You Need Invested to Match It.

247wallst.com · Jul 3, 2026

Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026?

fool.com · Jul 3, 2026

J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?

zacks.com · Jul 2, 2026

3 Dividend Stocks to Buy Hand Over Fist in July

247wallst.com · Jul 2, 2026

AbbVie: Apogee Deal Just Widened An Already Dominant Moat

seekingalpha.com · Jul 2, 2026

This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy?

fool.com · Jun 30, 2026

What Sparked the $43B Jump in AbbVie's Market Cap in the Past Week?

zacks.com · Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

proactiveinvestors.com · Jun 30, 2026

Genmab/AbbVie Lymphoma Trial Meets Main Goal, Analyst Eyes Bigger Market Opportunity

benzinga.com · Jun 30, 2026

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

zacks.com · Jun 30, 2026

Merck, AbbVie probed by US lawmakers over China clinical trials: report

proactiveinvestors.com · Jun 30, 2026

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

prnewswire.com · Jun 29, 2026

ABBV Gets CHMP Nod for Rinvoq in Two Different Autoimmune Diseases

zacks.com · Jun 29, 2026

Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs

zacks.com · Jun 29, 2026

3 No-Brainer Dividend Stocks to Buy Right Now

fool.com · Jun 29, 2026

AbbVie Stock Hits a New 52-Week High. Has It Gotten Too Expensive to Buy?

fool.com · Jun 29, 2026

AbbVie (ABBV) Moves 4.2% Higher: Will This Strength Last?

zacks.com · Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

gurufocus.com · Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

prnewswire.com · Jun 29, 2026

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

prnewswire.com · Jun 29, 2026

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

prnewswire.com · Jun 26, 2026

Lilly, J&J and AbbVie Hit New Highs

gurufocus.com · Jun 26, 2026

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

prnewswire.com · Jun 26, 2026

AbbVie vs. Pfizer: Which Pharma Giant Stock Is a Better Buy in 2026?

fool.com · Jun 25, 2026

Is AbbVie a Buy After Its Purchase of Apogee?

fool.com · Jun 25, 2026

3 Under-the-Radar Biotech Takeover Targets for the Next Pharma Buying Spree

247wallst.com · Jun 25, 2026

Why I Can't Stop Buying This Unstoppable Dividend Juggernaut

247wallst.com · Jun 24, 2026

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

gurufocus.com · Jun 24, 2026

Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE

businesswire.com · Jun 24, 2026

AbbVie's $11 Billion Immunology Bet

forbes.com · Jun 24, 2026

AbbVie Gets EU Nod for Skyrizi in Pediatric Plaque Psoriasis

zacks.com · Jun 24, 2026

64 Years Old With $1.1 Million in a Traditional IRA. Here’s Where I’m Allocating Capital

247wallst.com · Jun 24, 2026

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

prnewswire.com · Jun 24, 2026

After Apogee, 3 More Biotech Buyout Targets Wall Street Can't Stop Watching

247wallst.com · Jun 24, 2026

AbbVie's Costly Apogee Acquisition Has Long-Term Upside: Analyst

benzinga.com · Jun 23, 2026

Why Is AbbVie Up or Down Today?

When AbbVie (ABBV) moves sharply, the reason is almost always in the headlines above. Earnings, guidance, analyst upgrades and downgrades, product news and macro data are the usual drivers of a ABBV move on the day. The feed shows what broke and when, and the sentiment tag on each story shows whether the coverage skews positive or negative, so you can see at a glance why AbbVie is up or down today.

How AbbVie News Affects the Price

News does not move the AbbVie (ABBV) price directly, it moves sentiment, and sentiment moves price. A run of negative headlines pulls the AbbVie Fear and Greed Index toward fear, while positive coverage pushes it toward greed, often before the price has fully reacted. A surprise story usually shows up first as a spike in AbbVie trading volume. That is the chain to watch: headline, sentiment, volume, then the ABBV price.

Trade the AbbVie News With Sentiment

Headlines tell you what happened; the Fear and Greed Index tells you how the crowd is reacting. Watch AbbVie trading volume spike on a big story, check the AbbVie price history for context, follow the live ABBV price, see the AbbVie price prediction, and read the AbbVie Fear and Greed Index for mood.

How do you feel about AbbVie?

1D

Frequently asked questions

Why is AbbVie up or down today?
AbbVie (ABBV) moves on news, and the headlines above are the fastest way to see what is driving ABBV today, from earnings, guidance and analyst moves to the broader market mood. Cross-check the reaction against the live AbbVie Fear and Greed Index and ABBV trading volume.
What is the latest AbbVie news?
The newest AbbVie (ABBV) headlines are listed above, most recent first, each linking to the original source. We pull the last 60 stories so you can scroll the full recent ABBV news cycle in one place.
Where does AbbVie news come from?
We aggregate AbbVie (ABBV) headlines from financial news wires and refresh them continuously. Each headline links straight to the original source.
How often is AbbVie news updated?
Continuously. The AbbVie (ABBV) feed refreshes as new stories are published, so the headlines at the top are the freshest available.
How does AbbVie news relate to its Fear and Greed Index?
News drives sentiment, and sentiment drives price. A run of negative headlines tends to push the AbbVie Fear and Greed Index toward fear, positive coverage toward greed. Reading them together is how you separate noise from a real shift in mood.

Headlines are aggregated from third-party sources and link to the original publishers. CFGI does not author or endorse them.

About CFGI

The per-asset sentiment record.

CFGI is a market sentiment data company that scores crowd emotion from 0 to 100 across crypto and stock markets. Crypto readings cover the whole market and hundreds of individual assets across 15-minute, 1-hour, 4-hour and daily views. The stock index gives a live daily reading for wider stock market sentiment.

Every CFGI score is built from 10 indicators: price, volatility, volume, impulse, technical analysis, social media, dominance, search interest, whale movements and order book pressure. The same data powers our API, alerts and embeddable widgets.